|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
CA2835607C
(en)
|
2011-07-01 |
2021-07-20 |
Ngm Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
PH12019502809B1
(en)
|
2012-06-13 |
2024-04-24 |
Incyte Holdings Corp |
Substituted tricyclic compounds as fgfr inhibitors
|
|
PT2872491T
(pt)
|
2012-07-11 |
2021-08-05 |
Blueprint Medicines Corp |
Inibidores do recetor do fator de crescimento de fibroblastos
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
EP2925775B1
(en)
|
2012-11-28 |
2020-09-16 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9925242B2
(en)
|
2012-12-27 |
2018-03-27 |
Ngm Biopharmaceuticals, Inc. |
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
JP6576325B2
(ja)
*
|
2013-03-15 |
2019-09-18 |
セルジーン シーエーアール エルエルシー |
ヘテロアリール化合物およびそれらの使用
|
|
UA120248C2
(uk)
|
2013-03-15 |
2019-11-11 |
Селджен Кар Ллс |
Гетероарильні сполуки та їх застосування
|
|
AR095464A1
(es)
|
2013-03-15 |
2015-10-21 |
Celgene Avilomics Res Inc |
Compuestos de heteroarilo y usos de los mismos
|
|
MY181497A
(en)
|
2013-04-19 |
2020-12-23 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US9783504B2
(en)
*
|
2013-07-09 |
2017-10-10 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
US9550770B2
(en)
|
2013-08-23 |
2017-01-24 |
Neupharma, Inc. |
Substituted quinazolines for inhibiting kinase activity
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
HRP20181388T1
(hr)
|
2013-10-17 |
2018-10-19 |
Blueprint Medicines Corporation |
Pripravci koji su korisni u liječenju poremećaja povezanih s enzimom kit
|
|
AR098048A1
(es)
*
|
2013-10-18 |
2016-04-27 |
Eisai R&D Man Co Ltd |
Inhibidores de fgfr4
|
|
AU2014339972B9
(en)
|
2013-10-25 |
2019-05-30 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
BR112016008276B1
(pt)
|
2013-10-25 |
2021-03-02 |
Novartis Ag |
derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
|
|
RU2707531C2
(ru)
|
2013-10-28 |
2019-11-27 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Модели рака и соответствующие способы
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
SG11201605699QA
(en)
|
2014-01-20 |
2016-08-30 |
Cleave Biosciences Inc |
FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
|
|
CA2937898C
(en)
|
2014-01-24 |
2025-05-06 |
Ngm Biopharmaceuticals, Inc. |
Antibodies that bind to beta-klotho and their uses
|
|
ES2689421T3
(es)
*
|
2014-02-07 |
2018-11-14 |
Principia Biopharma Inc. |
Derivados de quinolina como inhibidores de los receptores de los factores de crecimiento de fibroblastos
|
|
EP3114124A1
(en)
|
2014-03-03 |
2017-01-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
CA2951153A1
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
WO2016027781A1
(ja)
|
2014-08-18 |
2016-02-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
単環ピリジン誘導体の塩およびその結晶
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
ES2756748T3
(es)
|
2014-10-03 |
2020-04-27 |
Novartis Ag |
Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
RU2729161C2
(ru)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
|
WO2016133935A1
(en)
*
|
2015-02-17 |
2016-08-25 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
PE20171514A1
(es)
|
2015-02-20 |
2017-10-20 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
*
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
CN107667092B
(zh)
|
2015-03-25 |
2021-05-28 |
诺华股份有限公司 |
作为fgfr4抑制剂的甲酰化n-杂环衍生物
|
|
SG11201706143SA
(en)
|
2015-03-25 |
2017-09-28 |
Nat Cancer Ct |
Therapeutic agent for bile duct cancer
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
JP6431622B2
(ja)
|
2015-04-14 |
2018-11-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
結晶性ｆｇｆｒ４阻害剤化合物およびその使用
|
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
EP3298011B1
(en)
*
|
2015-05-22 |
2021-11-17 |
Principia Biopharma Inc. |
Quinolone derivatives as fibroblast growth factor receptor inhibitors
|
|
CN113149983B
(zh)
|
2015-06-03 |
2024-03-29 |
普林斯匹亚生物制药公司 |
酪氨酸激酶抑制剂
|
|
BR112018000808A2
(pt)
|
2015-07-16 |
2018-09-04 |
Array Biopharma Inc |
compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
AU2016297754A1
(en)
|
2015-07-24 |
2018-02-15 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to KIT and PDGFR
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
CA2993356C
(en)
*
|
2015-08-11 |
2021-01-19 |
Principia Biopharma, Inc. |
Processes for preparing an fgfr inhibitor
|
|
JP6877407B2
(ja)
|
2015-08-26 |
2021-05-26 |
ブループリント メディシンズ コーポレイション |
Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3365335B1
(en)
*
|
2015-10-23 |
2024-02-14 |
Array Biopharma, Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
|
|
BR112018008357A2
(en)
|
2015-10-26 |
2018-11-27 |
Loxo Oncology, Inc. |
dot mutations in trk inhibitor resistant cancer and related methods
|
|
EA038890B1
(ru)
|
2015-11-02 |
2021-11-03 |
Блюпринт Медсинс Корпорейшн |
Ингибиторы ret
|
|
EP3888672A1
(en)
|
2015-11-09 |
2021-10-06 |
NGM Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
KR20240113606A
(ko)
|
2015-11-16 |
2024-07-22 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
JP2019500328A
(ja)
|
2015-11-19 |
2019-01-10 |
ブループリント メディシンズ コーポレイション |
Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物
|
|
CN115177619A
(zh)
|
2015-12-17 |
2022-10-14 |
卫材R&D管理有限公司 |
用于乳腺癌的治疗剂
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
US10183928B2
(en)
|
2016-03-17 |
2019-01-22 |
Blueprint Medicines Corporation |
Inhibitors of RET
|
|
FI3439662T3
(fi)
|
2016-04-04 |
2024-09-04 |
Loxo Oncology Inc |
(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
RS65988B1
(sr)
|
2016-04-04 |
2024-10-31 |
Loxo Oncology Inc |
Postupak lečenja pedijatrijskih karcinoma
|
|
AU2017250302B2
(en)
|
2016-04-15 |
2021-01-21 |
Blueprint Medicines Corporation |
Inhibitors of activin receptor-like kinase
|
|
US11357769B2
(en)
|
2016-05-10 |
2022-06-14 |
Eisai R&D Management Co., Ltd. |
Drug combinations for reducing cell viability and/or cell proliferation
|
|
HRP20201984T1
(hr)
|
2016-05-18 |
2021-04-16 |
Loxo Oncology, Inc. |
Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
KR20180002053A
(ko)
*
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
EP4006035B1
(en)
|
2016-08-15 |
2023-11-22 |
Neupharma, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
ES2859637T3
(es)
*
|
2016-09-01 |
2021-10-04 |
Nanjing Transthera Biosciences Co Ltd |
Inhibidores del receptor de factor de crecimiento de los fibroblastos y uso de los mismos
|
|
CN110022900A
(zh)
*
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
JOP20190077A1
(ar)
|
2016-10-10 |
2019-04-09 |
Array Biopharma Inc |
مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
RU2742033C2
(ru)
|
2016-11-02 |
2021-02-01 |
Новартис Аг |
Комбинации ингибиторов fgfr4 и секвестрантов желчных кислот
|
|
KR102249632B1
(ko)
*
|
2016-11-17 |
2021-05-10 |
광동 쫑성 파마세티컬 컴패니, 리미티드 |
Fgfr4 억제제, 이의 제조 방법 및 응용
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
US10968220B2
(en)
*
|
2016-12-19 |
2021-04-06 |
Abbisko Therapeutics Co., Ltd. |
FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
WO2018136661A1
(en)
|
2017-01-18 |
2018-07-26 |
Andrews Steven W |
SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
WO2018183712A1
(en)
|
2017-03-31 |
2018-10-04 |
Blueprint Medicines Corporation |
Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
SG11202001979PA
(en)
*
|
2017-09-05 |
2020-04-29 |
Bioardis Llc |
Aromatic derivative, preparation method for same, and medical applications thereof
|
|
TWI876442B
(zh)
|
2017-10-10 |
2025-03-11 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
EP3697786B1
(en)
|
2017-10-18 |
2022-08-31 |
Blueprint Medicines Corporation |
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
|
|
SI3697789T1
(sl)
|
2017-10-18 |
2022-04-29 |
Incyte Corporation |
Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
|
|
JOP20180094A1
(ar)
|
2017-10-18 |
2019-04-18 |
Hk Inno N Corp |
مركب حلقي غير متجانس كمثبط بروتين كيناز
|
|
WO2019085894A1
(zh)
*
|
2017-10-30 |
2019-05-09 |
如东凌达生物医药科技有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
CN111630054B
(zh)
|
2018-01-18 |
2023-05-09 |
奥瑞生物药品公司 |
作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
|
|
WO2019143977A1
(en)
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
TW201932464A
(zh)
|
2018-01-18 |
2019-08-16 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
|
|
JP7168149B2
(ja)
*
|
2018-02-08 |
2022-11-09 |
▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 |
Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
|
|
CN111712245A
(zh)
|
2018-03-28 |
2020-09-25 |
卫材R&D管理有限公司 |
用于肝细胞癌的治疗剂
|
|
WO2019195471A1
(en)
|
2018-04-03 |
2019-10-10 |
Blueprint Medicines Corporation |
Ret inhibitor for use in treating cancer having a ret alteration
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
JP7568512B2
(ja)
|
2018-05-04 |
2024-10-16 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の塩
|
|
CN112867716B
(zh)
|
2018-05-04 |
2024-09-13 |
因赛特公司 |
Fgfr抑制剂的固体形式和其制备方法
|
|
CN111868058B
(zh)
*
|
2018-05-25 |
2023-06-13 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
CN112313207B
(zh)
*
|
2018-06-22 |
2023-02-14 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
KR102612513B1
(ko)
|
2018-07-31 |
2023-12-12 |
록쏘 온콜로지, 인코포레이티드 |
(s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
|
|
US12134620B2
(en)
|
2018-08-01 |
2024-11-05 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
WO2020055672A1
(en)
|
2018-09-10 |
2020-03-19 |
Array Biopharma Inc. |
Fused heterocyclic compounds as ret kinase inhibitors
|
|
WO2020052349A1
(zh)
*
|
2018-09-14 |
2020-03-19 |
上海和誉生物医药科技有限公司 |
Fgfr抑制剂、其制备方法和应用
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
WO2020177067A1
(en)
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
CN113646314B
(zh)
*
|
2019-03-08 |
2023-12-08 |
首药控股(北京)股份有限公司 |
Fgfr4激酶抑制剂及其制备方法和用途
|
|
EP4302761A3
(en)
|
2019-04-12 |
2024-03-27 |
Blueprint Medicines Corporation |
Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4006027B1
(en)
|
2019-07-26 |
2025-10-01 |
CGeneTech (Suzhou, China) Co., Ltd. |
Pyridine derivative as fgfr and vegfr dual inhibitors for the treatment of cancer
|
|
CN114174270B
(zh)
*
|
2019-08-08 |
2023-06-06 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
|
|
EP4011869B1
(en)
*
|
2019-08-08 |
2023-11-15 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Crystal form d of pyrazine-2(1h)-ketone compound and preparation method therefor
|
|
EP4011868B1
(en)
|
2019-08-08 |
2025-01-01 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Pyrazine-2(1h)-ketone compound preparation method
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11607416B2
(en)
|
2019-10-14 |
2023-03-21 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
US11897891B2
(en)
|
2019-12-04 |
2024-02-13 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
EP4069369A4
(en)
|
2019-12-06 |
2024-02-14 |
Schrödinger, Inc. |
CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
|
|
US20230125046A1
(en)
*
|
2019-12-23 |
2023-04-20 |
Beijing Scitech-Mq Pharmaceuticals Limited |
Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof
|
|
BR112022012684A2
(pt)
|
2019-12-27 |
2023-03-07 |
Schroedinger Inc |
Compostos cíclicos e métodos de uso dos mesmos
|
|
WO2021146424A1
(en)
*
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021243192A1
(en)
|
2020-05-29 |
2021-12-02 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
WO2021247971A1
(en)
*
|
2020-06-05 |
2021-12-09 |
Kinnate Biopharma Inc. |
Inhibitors of fibroblast growth factor receptor kinases
|
|
CN116490507A
(zh)
|
2020-09-10 |
2023-07-25 |
薛定谔公司 |
用于治疗癌症的杂环包缩合cdc7激酶抑制剂
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
CN116783192B
(zh)
*
|
2021-01-26 |
2025-10-31 |
盛世泰科生物医药技术(苏州)股份有限公司 |
甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
|
|
EP4284804A1
(en)
|
2021-01-26 |
2023-12-06 |
Schrödinger, Inc. |
Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
TW202402754A
(zh)
*
|
2021-03-04 |
2024-01-16 |
美商美國禮來大藥廠 |
Fgfr3抑制劑化合物
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
EP4317143A4
(en)
*
|
2021-03-26 |
2025-01-15 |
Hangzhou Apeloa Medicine Research Institute Co., Ltd. |
BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION THEREOF AND USE THEREOF
|
|
CA3215903A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
JP2024522188A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
WO2024242495A1
(ko)
*
|
2023-05-25 |
2024-11-28 |
주식회사 매직불릿테라퓨틱스 |
단백질 키나아제 억제용 신규 화합물 및 이를 포함하는 약학조성물
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
WO2025059027A1
(en)
|
2023-09-11 |
2025-03-20 |
Schrödinger, Inc. |
Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
|